UroToday3d
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy.
As multiple front-line immune checkpoint inhibitor (ICI)-based combinations are approved for metastatic renal cell carcinoma, biomarkers predicting for ICI responses are needed past clinical ...
UroToday4d
Networks of pre-diagnostic circulating RNA in testicular germ cell tumour.
Testicular germ cell tumour (TGCT) is a malignancy with known inherited risk factors, affecting young men. We have previously identified several hundred differentially abundant circulating RNAs in pre ...
UroToday4d
The Clinical Role of Hypoxia Inducible Factor (HIF) Inhibition in Renal Cancer: A Focus on Belzutifan.
Systemic therapy for metastatic Renal Cell Carcinoma (mRCC) has dramatical-ly improved in the last years because of the use of immunotherapy with checkpoint inhibi-tor combinations with or without ...
UroToday5d
Diagnostic Accuracy of VI-RADS for Determining Muscle Invasion - Expert Commentary
Treatment selection in bladder cancer (BC) depends on the accurate determination of muscle invasion in transurethral resection of bladder tumor (TURBT). However, there are various limitations to TURBT ...
UroToday5d
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.
Aggressive variant prostate cancer (AVPC) is characterized by a molecular signature involving combined defects in TP53, RB1, and/or PTEN (AVPC-TSGs), identifiable through immunohistochemistry or ...
UroToday4d
Paediatric renal tumours: an update on challenges and recent developments.
Paediatric renal tumours include a broad range of neoplasms which largely differ, but also overlap to a smaller extent, with adult kidney cancer. These include the embryonal tumour nephroblastoma, ...
UroToday4d
The interaction of structured data using openEHR and large Language models for clinical decision support in prostate cancer.
Multidisciplinary teams (MDTs) are essential for cancer care but are resource-intensive. Decision-making processes within MDTs, while critical, contribute to increased healthcare costs due to the need ...
UroToday4d
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal.
Using joint genomic-transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor ...
UroToday6d
Increased Translation Driven by Non-Canonical EZH2 Creates a Synthetic Vulnerability in Enzalutamide-Resistant Prostate Cancer - Beyond the Abstract
Prostate cancer (PC) treatment remains a challenge, particularly in its advanced, castration-resistant form (CRPC), where resistance to androgen receptor (AR)-targeted therapies, such as enzalutamide ...
UroToday5d
Point-Based Prediction Model for Bladder Cancer Risk in Diabetes: A Random Survival Forest-Guided Approach.
Background: Previous epidemiological studies have shown that diabetes is associated with an increased risk of several cancers, including bladder cancer. However, prediction models for bladder cancer ...
UroToday5d
Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128).
Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard of care for RCC patients who are at high risk of recurrence.
UroToday4d
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience.
Advanced penile squamous cell carcinoma (pSCC) is a rare and aggressive malignancy with a poor prognosis and an unmet need for biomarkers. We performed a retrospective evaluation of real-world ...